FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220778872> ?p ?o ?g. }

• W4220778872 endingPage "627" @default.
• W4220778872 startingPage "616" @default.
• W4220778872 abstract "In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at a median follow-up of 27 months and key patient-reported outcomes (PROs) are presented.The safety population included all patients who received at least one dose of study treatment (n = 5591). Safety analyses included incidence, management, and outcomes of common and clinically relevant adverse events (AEs). Patient-reported health-related quality of life, ET symptoms, fatigue, and side-effect burden were assessed.The addition of abemaciclib to ET resulted in higher incidence of grade ≥3 AEs (49.7% versus 16.3% with ET alone), predominantly laboratory cytopenias [e.g. neutropenia (19.6%)] without clinical complications. Abemaciclib-treated patients experienced more serious AEs (15.2% versus 8.8%). Discontinuation of abemaciclib and/or ET due to AEs occurred in 18.5% of patients, mainly due to grade 1/2 AEs (66.8%). AEs were managed with comedications (e.g. antidiarrheals), abemaciclib dose holds (61.7%), and/or dose reductions (43.4%). Diarrhea was generally low grade (grade 1/2: 76%); grade 2/3 events were highest in the first month (20.5%), most were short-lived (≤7 days) and did not recur. Venous thromboembolic events (VTEs) were higher with abemaciclib + ET (2.5%) versus ET (0.6%); in the abemaciclib arm, increased VTE risk was observed with tamoxifen versus aromatase inhibitors (4.3% versus 1.8%). PROs were similar between arms, including being 'bothered by side-effects of treatment', except for diarrhea. At ≥3 months, most patients reporting diarrhea reported 'a little bit' or 'somewhat'.In patients with high-risk EBC, adjuvant abemaciclib + ET has an acceptable safety profile and tolerability is supported by PRO findings. Most AEs were reversible and manageable with comedications and/or dose modifications, consistent with the known abemaciclib toxicity profile." @default.
• W4220778872 created "2022-04-03" @default.
• W4220778872 creator A5002068827 @default.
• W4220778872 creator A5003889471 @default.
• W4220778872 creator A5008382382 @default.
• W4220778872 creator A5010302931 @default.
• W4220778872 creator A5021671041 @default.
• W4220778872 creator A5031915637 @default.
• W4220778872 creator A5034863656 @default.
• W4220778872 creator A5038422646 @default.
• W4220778872 creator A5045327505 @default.
• W4220778872 creator A5046443212 @default.
• W4220778872 creator A5046758725 @default.
• W4220778872 creator A5048281465 @default.
• W4220778872 creator A5052268554 @default.
• W4220778872 creator A5055059973 @default.
• W4220778872 creator A5056916984 @default.
• W4220778872 creator A5057504469 @default.
• W4220778872 creator A5069056507 @default.
• W4220778872 creator A5071432873 @default.
• W4220778872 creator A5071553983 @default.
• W4220778872 creator A5086213012 @default.
• W4220778872 creator A5090188675 @default.
• W4220778872 creator A5091245889 @default.
• W4220778872 date "2022-06-01" @default.
• W4220778872 modified "2023-10-17" @default.
• W4220778872 title "Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study" @default.
• W4220778872 cites W1977733462 @default.
• W4220778872 cites W2195040438 @default.
• W4220778872 cites W2620925856 @default.
• W4220778872 cites W2896846857 @default.
• W4220778872 cites W2909997301 @default.
• W4220778872 cites W3087561595 @default.
• W4220778872 cites W3097489112 @default.
• W4220778872 cites W3120214437 @default.
• W4220778872 cites W3136400004 @default.
• W4220778872 cites W3206169364 @default.
• W4220778872 cites W4206349107 @default.
• W4220778872 doi "https://doi.org/10.1016/j.annonc.2022.03.006" @default.
• W4220778872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35337972" @default.
• W4220778872 hasPublicationYear "2022" @default.
• W4220778872 type Work @default.
• W4220778872 citedByCount "31" @default.
• W4220778872 countsByYear W42207788722016 @default.
• W4220778872 countsByYear W42207788722017 @default.
• W4220778872 countsByYear W42207788722022 @default.
• W4220778872 countsByYear W42207788722023 @default.
• W4220778872 crossrefType "journal-article" @default.
• W4220778872 hasAuthorship W4220778872A5002068827 @default.
• W4220778872 hasAuthorship W4220778872A5003889471 @default.
• W4220778872 hasAuthorship W4220778872A5008382382 @default.
• W4220778872 hasAuthorship W4220778872A5010302931 @default.
• W4220778872 hasAuthorship W4220778872A5021671041 @default.
• W4220778872 hasAuthorship W4220778872A5031915637 @default.
• W4220778872 hasAuthorship W4220778872A5034863656 @default.
• W4220778872 hasAuthorship W4220778872A5038422646 @default.
• W4220778872 hasAuthorship W4220778872A5045327505 @default.
• W4220778872 hasAuthorship W4220778872A5046443212 @default.
• W4220778872 hasAuthorship W4220778872A5046758725 @default.
• W4220778872 hasAuthorship W4220778872A5048281465 @default.
• W4220778872 hasAuthorship W4220778872A5052268554 @default.
• W4220778872 hasAuthorship W4220778872A5055059973 @default.
• W4220778872 hasAuthorship W4220778872A5056916984 @default.
• W4220778872 hasAuthorship W4220778872A5057504469 @default.
• W4220778872 hasAuthorship W4220778872A5069056507 @default.
• W4220778872 hasAuthorship W4220778872A5071432873 @default.
• W4220778872 hasAuthorship W4220778872A5071553983 @default.
• W4220778872 hasAuthorship W4220778872A5086213012 @default.
• W4220778872 hasAuthorship W4220778872A5090188675 @default.
• W4220778872 hasAuthorship W4220778872A5091245889 @default.
• W4220778872 hasBestOaLocation W42207788721 @default.
• W4220778872 hasConcept C121608353 @default.
• W4220778872 hasConcept C126322002 @default.
• W4220778872 hasConcept C143998085 @default.
• W4220778872 hasConcept C197934379 @default.
• W4220778872 hasConcept C207103383 @default.
• W4220778872 hasConcept C2776694085 @default.
• W4220778872 hasConcept C2777063308 @default.
• W4220778872 hasConcept C2777176818 @default.
• W4220778872 hasConcept C2778715236 @default.
• W4220778872 hasConcept C2908647359 @default.
• W4220778872 hasConcept C44249647 @default.
• W4220778872 hasConcept C530470458 @default.
• W4220778872 hasConcept C71924100 @default.
• W4220778872 hasConcept C90924648 @default.
• W4220778872 hasConcept C99454951 @default.
• W4220778872 hasConceptScore W4220778872C121608353 @default.
• W4220778872 hasConceptScore W4220778872C126322002 @default.
• W4220778872 hasConceptScore W4220778872C143998085 @default.
• W4220778872 hasConceptScore W4220778872C197934379 @default.
• W4220778872 hasConceptScore W4220778872C207103383 @default.
• W4220778872 hasConceptScore W4220778872C2776694085 @default.
• W4220778872 hasConceptScore W4220778872C2777063308 @default.
• W4220778872 hasConceptScore W4220778872C2777176818 @default.
• W4220778872 hasConceptScore W4220778872C2778715236 @default.
• W4220778872 hasConceptScore W4220778872C2908647359 @default.
• W4220778872 hasConceptScore W4220778872C44249647 @default.
• W4220778872 hasConceptScore W4220778872C530470458 @default.

• next